| abstract |
The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8 + cytotoxic T lymphocyte (CTL) activity, attenuates tumors, and thereby inhibits tumor formation. Accordingly, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods of providing anti-tumor immunity in a subject, stimulating A method of T cell mediated immune response to a cell population or tissue and inhibiting a tumor in a subject. Additionally, the present invention includes methods of diagnosing cancer or a predisposition to develop cancer or metastases, as well as methods of determining the use of immunotherapy treatments or cancer vaccines for the treatment of cancer. In addition, the present invention includes pharmaceutical compositions for treating cancer and kits for practicing the above methods. |